Peramivir injection in the treatment of acute influenza: A review of the literature

Infection and Drug Resistance

Volumn 9, Issue , 2016, Pages 201-214

  Wester, Ashley ^a   Shetty, Avinash K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy; Influenza; Peramavir; Pharmacokinetics; Review; Safety

Indexed keywords

ADAMANTANE DERIVATIVE; FAVIPIRAVIR; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; SIALIDASE; SIALIDASE INHIBITOR;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; BEHAVIOR DISORDER; BINDING AFFINITY; CONSTIPATION; CRITICALLY ILL PATIENT; DELIRIUM; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EPIDEMIC; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; EXTRACORPOREAL OXYGENATION; HOSPITAL PATIENT; HUMAN; HYPERSENSITIVITY; HYPERTENSION; IC50; IN VITRO STUDY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; INSOMNIA; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MICROBIOLOGY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; PANDEMIC; PATIENT CARE; PREGNANT WOMAN; RENAL REPLACEMENT THERAPY; REVIEW; SEASONAL INFLUENZA; SINGLE DRUG DOSE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; VOMITING;

EID: 84989181210     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S86460     Document Type: Review

References (70)

1. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonias. Lancet. 2011;377(9773):1264–1275.
2. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines. MMWR Morb Mortal Wkly Rep. 2010;59(RR-8):1–62.
3. World Health Organization (WHO). Influenza (seasonal). Fact Sheet; March 2014. Geneva, Switzerland: World Health Organization; 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed June 23, 2014.
4. Girard MP, Cherian T, Pervikov Y, Kieny MP. A review of vaccine research and development: human acute respiratory infections. Vaccine. 2005;23(50):5708–5724.
5. Shrestha SS, Swerdlow DL, Borse RH. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–2010). Clin Infect Dis. 2011;52(Suppl 1):S75–S82.
6. Louie JK, Acosta M, Winter K, et al and the California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA. 2009;302(17):1896–1902.
7. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(Suppl 1):S3–S13.
8. Yu Y, Garg S, Patricia A, et al. Peramivir use for treatment of hospitalized patients with influenza A (H1N1) pdm09 under emergency use authorization, October 2009–June 2010. Clin Infect Dis. 2012;55(1):8–15.
9. Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis. 2012;55(1):1–7.
10. Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther. 2014;8: 2017–2038.
11. Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence. Expert Rev Anti Infect Ther. 2015;13(4):417–425.
12. McLaughlin MM, Skoglund EW, Ison MG. Peramivir: an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015;16(12): 1889–1900.
13. US Food and Drug Administration. FDA approves Rapivab to treat flu infection. Silver Spring, MD: US Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm. Accessed June 23, 2015.
14. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363–1373.
15. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 1998;42(3):647–653.
16. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 1996;275(4):295–299.
17. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54(9):3671–3677.
18. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42(3):640–646.
19. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000;43(19):3482–3486.
20. Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69(1):39–45.
21. Bantia S, Upshaw R, Babu YS. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme. Antiviral Res. 2011;91(3):288–291.
22. Mineno T, Miller MJ. Stereoselective total synthesis of racemic BCX- 1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents. J Org Chem. 2003;68(17):6591–6596.
23. Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drugs Today (Barc) 2010;46(6):399–408.
24. Beigel J, Harmon LA, Collis PJ, et al. Pharmacokinetics and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17–20, 2007; Chicago, IL. Abstract A-1408.
25. Barroso L, Treanor J, Gubareva L, et al. Efficacy and tolerability of the oral neuraminidase inhibitor in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 2005;10(8):901–910.
26. Atiee G, Collis P, McCullough A, Dobo S, Elder J, Sheridan B. Single dose injections of i.v. and i.m. peramivir are bioequivalent and well tolerated. Poster presented at: Interscience Conference on Antimicrobial Agents Chemotherapy; September 5–9; 2014; Washington, DC.
27. Matsuo Y, Ishibashi T, Hollister AS, Wajima T. Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. Antimicrob Agents Chemother. 2015;59(11):6755–6762.
28. Zhang D, Du A, Zhang L, et al. Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects. Xenobiotica. 2014;45(3):239–243.
29. Sato M, Ito M, Suzuki S, et al. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants. Antimicrob Agents Chemother. 2015;59(3):1643–1649.
30. Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. Int J Clin Pharm Ther. 2014;52(12):1105–1111.
31. Tang X, He H, Sun B, et al. ARDS associated with pneumonia caused by avian influenza A H7N9 virus treated with extracorporeal membrane oxygenation. Clin Respir J. 2015;9(3):380–384.
32. Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother. 2001;45(10):2723–2732.
33. Farooqui A, Huang L, Wu S, et al. Assessment of antiviral properties of peramivir agains H7N9 avian influenza virus in an experimental mouse model. Antimicrob Agents Chemother. 2015;59(12):7255–7264.
34. Dapat C, Kondo H, Dapat IC, et al. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009–2010 and 2010–2011 influenza seasons in Japan. Antiviral Res. 2013;99(3):261–269.
35. Leang SK, Kwok S, Sullivan SG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses. 2013;8(2):135–139.
36. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 2007;74(2):159–162.
37. Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res. 2015;117:27–38.
38. Takashita E, Fujisaki S, Kishida N, et al. Characterization of neuraminidase inhibitor-resistant influenza A (H1N1) pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses. 2013;7(6):1390–1399.
39. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivirand peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50(9):1252–1255.
40. Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A (H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19(1):1–6.
41. Nguyen HT, Trujillo AA, Sheu TG, et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res. 2012;93(3):381–386.
42. Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir- resistant A (H1N1) pdm09 influenza. N Engl J Med. 2011;365(26): 2541–2542.
43. Sleeman K, Mishin VP, Guo Z, et al. Antiviral susceptibility of variant influenza A (H3N2) viruses isolated in the United States from 2011 to 2013. Antimicrob Agents Chemother. 2014;58(4):2045–2051.
44. Farrukee R, Mosse J, Hurt AC. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev Anti Infect Ther. 2013;11(11):1135–1145.
45. BioCryst Pharmaceuticals. Evaluation of the efficacy and safety of peramivir in subjects with uncomplicated acute influenza. Available from: https://clinicaltrials.gov/ct2/show/NCT00419263. NLM identifier: NCT00419263. Accessed November 30, 2015.
46. Atiee G, Laughlin A, Tellier G, et al. Virologic analysis of influenza viruses after therapy with a single intramuscular dose of the neuraminidase inhibitor peramivir versus placebo in patients with influenza in the outpatient setting. Presented at: 49th Annual Meeting of the Infectious Diseases Society of America; October 20–23; 2011; Boston, MA.
47. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568–4574.
48. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55(6):2803–2812.
49. Kohno S, Yen MY, Cheong HJ, et al. Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: a phase III randomized, double-blind study. Antimicrob Agents Chemother. 2011;55(11):5267–5276.
50. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther. 2013;18(5):651–661.
51. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis. 2011;52(6):696–706.
52. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59(12):e172–e185.
53. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J. 2014;9(2):228–232.
54. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349–361.
55. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic A (H1N1) influenza virus infection. Antimicrob Agents Chemother. 2012;56(1):369–377.
56. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors –oseltamivir, zanamivir, laninamivir, and peramivir – for treatment of influenza A (H3N2) and A (H1N1) pdm09 infection: an observational study in the 2010–2011 influenza season in Japan. J Infect Chemother. 2012;18(6):858–864.
57. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012;2012:1–4.
58. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1,000 hospitalized children. J Infect. 2011;63(4):288–294.
59. Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics. 2013;132(6):e1539–e1545.
60. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A (H1N1) pdm09. PLoS One. 2012;7(6):e40261.
61. Dunning J, Baillie JK, Cao B, et al. Antiviral combinations for severe influenza. Lancet Infect Dis. 2014;14(12):1259–1270.
62. Atiee G, Lasseter K, Baughman S, et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol. 2012;52(9):1410–1419.
63. Peramivir® (Rapivab) [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc.; 2014.
64. Dobo SM, Elder J, Collis P. Safety of peramivir in hospitalized influenza. Poster #1169 presented at: 53rd Annual Meeting of the Infectious Diseases Society of America; October 8–11; Philadelphia, PA.
65. Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. J Infect Chemother. 2014;20(11):689–695.
66. Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): a pediatric drug use investigation. J Infect Chemother. 2014; 21(3):194–201.
67. Hayashi K, Iwasa K, Morinaga A, Ono K, Yamada M. Exacerbation of myasthenia gravis by intravenous peramivir. Muscle Nerve. 2015:51(6): 935–936.
68. Harada-Shirado K, Ikeda K, Furukawa M, et al. Severe immune thrombocytopenia possibly elicited by the anti-influenza viral agent peramivir. Intern Med. 2014;53(20):2369–2371.
69. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010;182(4):357–363.
70. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008;3(10):e3410.1–6.